Venture Certified
| 기술평가보증기업(기금) | 2021-03-22 ~ 2023-03-21 | 20210102310 | 2021-03-22 |
| 벤처투자유형 | 2023-05-31 ~ 2026-05-30 | 20230531010014 | 2021-03-22 |
Revenue CAGR -83.3%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.1B | 0.7B | 0.0B |
| Operating Profit | -27.9B | -16.6B | -7.3B |
| Net Profit | -18.0B | -40.7B | -7.6B |
| Total Assets | 71.0B | 7.0B | 42.2B |
| Total Liabilities | 14.9B | 17.9B | 12.4B |
| Total Equity | 56.0B | -10.9B | 29.8B |
Operating Loss: Op. profit -28B
Revenue down 83% YoY
3 Consecutive Years of Net Loss
▼ 66.6%
▼ 133.9%
▼ 908.7%
▲ 143.6%
▼ 118.5%
| Name | Position | Role |
|---|---|---|
| 김세준 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "서울특별시 서초구",
"ceo_name": "김세준",
"certificate": [
{
"cert_number": "20210102310",
"changes": "",
"disclosure_date": "2021-03-22",
"first_cert_date": "2021-03-22",
"no": "1",
"type": "기술평가보증기업(기금)",
"valid_period": "2021-03-22 ~ 2023-03-21"
},
{
"cert_number": "20230531010014",
"changes": "",
"disclosure_date": "2023-05-31",
"first_cert_date": "2021-03-22",
"no": "2",
"type": "벤처투자유형",
"valid_period": "2023-05-31 ~ 2026-05-30"
}
],
"company_name": "(주)서지넥스",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 120640000,
"cost_of_sales": 0,
"current_assets": 750036000,
"current_liabilities": 342591000,
"gross_profit": 0,
"net_income": -760745000,
"net_income_bs": -760745000,
"non_current_assets": 3474097000,
"non_current_liabilities": 900000000,
"non_operating_expenses": 48806000,
"non_operating_income": 15316000,
"operating_profit": -727255000,
"revenue": 0,
"sga_expenses": 727255000,
"total_assets": 4224133000,
"total_equity": 2981542000,
"total_liabilities": 1242591000
},
"2023": {
"capital_stock": 120640000,
"cost_of_sales": 0,
"current_assets": 82742000,
"current_liabilities": 306965000,
"gross_profit": 72970000,
"net_income": -4072799000,
"net_income_bs": -4072799000,
"non_current_assets": 615966000,
"non_current_liabilities": 1483000000,
"non_operating_expenses": 3038382000,
"non_operating_income": 622144000,
"operating_profit": -1656561000,
"revenue": 72970000,
"sga_expenses": 1729531000,
"total_assets": 698708000,
"total_equity": -1091257000,
"total_liabilities": 1789965000
},
"2024": {
"capital_stock": 180966000,
"cost_of_sales": 0,
"current_assets": 5914395000,
"current_liabilities": 1488959000,
"gross_profit": 12175000,
"net_income": -1800463000,
"net_income_bs": -1800463000,
"non_current_assets": 1184410000,
"non_current_liabilities": 5347000,
"non_operating_expenses": 101329000,
"non_operating_income": 1088997000,
"operating_profit": -2788131000,
"revenue": 12175000,
"sga_expenses": 2800306000,
"total_assets": 7098805000,
"total_equity": 5604499000,
"total_liabilities": 1494306000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "2,000,016,000",
"changes": "2,000,016,000",
"date": "2021-10-15"
},
{
"amount": "2,000,016,000",
"changes": "2,000,016,000",
"date": "2021-10-15"
}
],
"main_products": "신약개발",
"phone": "02-592-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |